Resources Repository
-
ReviewPublication 2022Diagnostics for COVID-19: Moving from Pandemic Response to Control
Diagnostics are essential in managing the COVID-19 pandemic, with three primary methods for detecting SARS-CoV-2 …
Diagnostics are essential in managing the COVID-19 pandemic, with three primary methods for detecting SARS-CoV-2 infections. Each test type remains vital as we shift from responding to controlling the pandemic. Molecular tests, like PCR, are highly precise in identifying viral RNA and are endorsed by the WHO for confirming cases and guiding public health actions. Antigen rapid tests spot viral proteins and, while less accurate than molecular tests, are quicker, more affordable, simpler, and can…
Test Performance | Infectious Diseases | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Mathematical Models | State-Transition | Infectious Diseases | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | North America -
ArticlePublication 2023Out-of-Pocket Expenditures & Financial Risks Associated with Treatment of Vaccine-Preventable Diseases in Ethiopia
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases …
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases (VPDs) in Ethiopia. Through a cross-sectional costing analysis, data on OOP direct medical and nonmedical expenditures were collected from 995 households in 54 health facilities nationwide. The study focuses on VPDs in children under 5 years for pneumonia, diarrhea, measles, and pertussis, and in children under 15 years for meningitis. Mean OOP expenditures per disease episode ranged from $5·6 to…
Cost-Effectiveness Analysis | Costing Methods | Mathematical Models | Child/Nutrition | Chronic Disease/Risk | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2023Effects of Public Financing of Essential Maternal and Child Health Interventions Across Wealth Quintiles in Nigeria: An Extended Cost-Effectiveness Analysis
This study evaluates the potential health and financial risk protection benefits of public financing for …
This study evaluates the potential health and financial risk protection benefits of public financing for maternal, newborn, and child health (MNCH) interventions in Nigeria, focusing on different wealth quintiles. Employing extended cost-effectiveness analysis, the research assesses the impact of a policy ensuring zero out-of-pocket costs for 18 essential MNCH services. Three scenarios were modeled: status quo, uniform scale-up, and pro-poor scale-up. Findings suggest that a 5% increase in coverage for all quintiles could prevent significant…
Cost-Effectiveness Analysis | Health Outcomes | Mathematical Models | Maternal/Reproductive Health | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2023Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines …
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden.…
Cost-Effectiveness Analysis | Mathematical Models | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Chronic Disease/Risk | Social Determinants | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Economic Evaluations of Health System Strengthening Activities
Health system strengthening (HSS) activities should accompany disease-targeting interventions in low/middle-income countries (LMICs). Economic evaluations …
Health system strengthening (HSS) activities should accompany disease-targeting interventions in low/middle-income countries (LMICs). Economic evaluations provide information on how these types of investment might best be balanced but can be challenging. This paper conducted a systematic review to evaluate how researchers address these economic evaluation challenges. The authors searches produced 1978 studies, out of which they included 36. Most studies used data from prospective trials and calculated cost-effectiveness directly from these trial inputs, rather than…
Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Economic Value of Clinical Artificial Intelligence
Artificial intelligence (AI) is increasingly used in clinical applications. Nevertheless, its flexibility and difficulties around …
Artificial intelligence (AI) is increasingly used in clinical applications. Nevertheless, its flexibility and difficulties around collecting data on its clinical impacts make value assessment challenging. This article uses a value framework as the basis for assessing how AI may create value depending on how it is used. Authors also provide advice to health economists seeking to model AI’s clinical impacts. There are multiple ways that AI challenges traditional health technology assessment methodology. Authors highlight several…
Technology Assessment | Value of Information | Economics/Finance | Science/Technology | Global -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Cost-Effectiveness Analysis | Costing Methods | Evidence Synthesis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Global